Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis [Case Report]

Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment.

Mots clés

invasive fungal disease anti-PD 1 cerebral mucormycosis covid-associated pulmonary aspergillosis immunotherapy

Domaines

Médecine humaine et pathologie

Fichier principal

SERRIS_2022.pdf (1.35 Mo)

Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY - Paternité

Nathalie Pagès : Connectez-vous pour contacter le contributeur

https://ut3-toulouseinp.hal.science/hal-04062203

Soumis le : vendredi 7 avril 2023-13:37:25

Dernière modification le : lundi 22 avril 2024-11:24:02

Archivage à long terme le : samedi 8 juillet 2023-19:17:10

Dates et versions

hal-04062203 , version 1 (07-04-2023)

Licence

Paternité

Identifiants

HAL Id : hal-04062203 , version 1
DOI : 10.3389/fimmu.2022.900522
PUBMED : 35720319
PUBMEDCENTRAL : PMC9199385

Citer

Alexandra Serris, Amani Ouedrani, Fabrice Uhel, Marianne Gazzano, Vincent Bedarida, et al.. Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis [Case Report]. Frontiers in Immunology, 2022, 13, pp.900522. ⟨10.3389/fimmu.2022.900522⟩. ⟨hal-04062203⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

IRD PASTEUR INSU METEO CNRS OMP OMP-ECOLAB SORBONNE-UNIVERSITE SU-MEDECINE INRAE UP-SANTE INFINITY TOULOUSE-INP UNIV-UT3 UT3-TOULOUSEINP MYCO-MOL PASTEUR_UMR2000 CNRMA

73 Consultations

14 Téléchargements